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ABSTRACT: The present study aims to assess the effects of zinc supplementation on metabolic parameters in patients 
with type 2 diabetes. A literature search was conducted in PubMedTM, Google ScholarTM, and ScopusTM up to March 2018. 
Twenty randomized controlled trials met the predefined inclusion criteria and were included in the meta-analysis. Weighted 
mean difference (WMD) with 95% confidence intervals (CIs) were calculated for net changes in glycemic indices includ-
ing fasting blood glucose (FBG) and hemoglobin A1c (HbA1c), and in lipid markers including total cholesterol (TC), tri-
glyceride (TG), low-density lipoprotein cholesterol (LDL-c), and high density lipoprotein cholesterol (HDL-c). Subgroup 
analyses were performed based on intervention and study quality. Compared to controls, zinc supplementation signifi-
cantly reduced the concentrations of both FBG and HbA1c (FBG WMD: −19.66 mg/dL, 95% CI: −33.71, −5.62; HbA1c 
WMD: −0.43 mg/dL, 95% CI: −0.80, −0.07). The pooled estimate showed a significant decrease in serum TC and LDL-c, 
and increase in serum HDL-c levels in treatment group compared with the control group (TC WMD: −18.51 mg/dL, 
95% CI: −21.36, −15.66; LDL-c WMD: −4.80 mg/dL, 95% CI: −6.07, −3.53; HDL-c WMD: 1.45 mg/dL, 95% CI: 
1.40, 1.51). Subgroup analysis of “no co-supplement” intervention demonstrated significant differences for mean changes 
in HDL-c and FBG levels, whereas subgroup analysis of high quality studies showed significant differences for mean 
changes of LDL-c, HDL-c, and FBG levels. Results suggested that zinc supplementation reduces FBG, HbA1c and LDL-c 
levels and increases HDL-C levels; however, these changes were related to intervention and quality of studies.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic and progressive dis-
ease characterized by high blood glucose concentrations 
resulting from defects in insulin secretion and/or insulin 
action (1). The global prevalence of diabetes and pre-di-
abetes is increasing because of population growth, aging, 
urbanization, lifestyle changes, and the high prevalence 
of obesity (2). Diabetes has various adverse effects on the 
cardiovascular system, vision, kidney function, and the 
nervous system, leading to increased risk of morbidity 
and mortality (3). The number of people suffering from 
diabetes has risen from 108 million in 1980 to 422 mil-
lion in 2014, with high prevalence in middle- and low- 
income countries (4).
The mechanisms that result in type 2 diabetes mellitus 
(T2DM) development are complicated. Some studies sug-
gest supplementation with zinc may alter T2DM charac-
teristics, including dyslipidemia, chronic hyperglycemia, 
and insulin resistance (1). Both hypozincemia and hyper-
zincuria have been observed in diabetic patients, which 
may increase the incidence of bacterial attack due to over- 
expression of various inflammatory factors or may reduce 
zinc availability to the brain (5). Zinc, as an essential 
mineral, plays a critical role in various biological proc-
esses, including as a cofactor in antioxidant enzymes, 
and in insulin action and carbohydrate metabolism (6, 
7). Zinc is involved in insulin crystallization and insulin 
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signaling by inducing activation of the phosphoinositide 
3-kinase (PI3K)/Akt cascade, which mediates glucose 
metabolism (1). Animal and human studies have dem-
onstrated the beneficial effects of zinc supplementation 
on fasting insulin levels, and fasting glucose and lipid 
profiles in both type-1 and type-2 diabetic patients; how-
ever, may of these results have been contradicted in oth-
er studies. A systemic review and meta-analysis of the 
effect of zinc supplementation on diabetes was performed 
by Jayawardena et al. (8). The authors observed that zinc 
exhibits beneficial effect on glycemic control, lipid pa-
rameters, and systolic and diastolic blood pressure. How-
ever, in another meta-analysis by Foster et al. (9), no 
beneficial effects of zinc supplementation were observed 
on lipid profiles in humans.
Currently, there are no up-to-date systemic reviews or 
meta-analyses examining zinc supplementation on glyce-
mic control and lipid parameters in subjects with T2DM 
based on intervention and study qualities. The present 
study aimed to systematically assess the effects of zinc 
supplementation on markers of glycemic control [glucose, 
insulin, and hemoglobin A1c (HbA1c)] and lipid profiles 
[total cholesterol (TC), low-density lipoprotein cholester-
ol (LDL-c), high density lipoprotein cholesterol (HDL-c), 
and triglycerides (TG)] in humans, and to conduct a met-
a-analysis of qualified controlled trials to quantify the ef-
fect of zinc supplementation.
MATERIALS AND METHODS
This study was conducted in accordance with the Prefer-
red Reporting Items for Systematic reviews and Meta- 
Analysis (PRISMA) statement for interventional research 
(10).
Search strategy and study selection
A comprehensive search was conducted from January 
1990 to March 2018. The PubmedTM database, Google 
ScholarTM, and ScopusTM were used to obtain relevant ar-
ticles based on inclusion criteria. Two groups of medical 
subject headings (MeSH) and non-MeSH keywords were 
used as search terms. Group 1: “Zn”, “zinc”, and “zinc 
supplementation”; group 2: “glycemic control”, and lipid 
indices (“cholesterol”, “plasma lipids”, “triglycerides”, 
“HDL-c”, “LDL-c”, “serum lipids”, “FBS”, “FBG”, “fast-
ing blood glucose”, “diabetes”, or “T2DM”). Studies were 
limited to those in human, clinical trials, and those pub-
lished in English. The titles and abstracts were screened 
to determine study eligibility. Studies were retrieved if 
they were human clinical trials that measured the effects 
of zinc supplementation on at least one of the following 
outcomes: changes in HDL-c, LDL-c, TC, TG, fasting 
blood glucose (FBG), and HbA1c.
Inclusion criteria
We used the following inclusion criteria: 1) controlled 
trial; 2) studies focusing on the effect of Zn on glycemic 
control, including HDL-c, LDL-c, TG, TC, FBG, and 
HbA1c; 3) age of study population ≥18 year; and 4) pa-
tients with type 2 diabetes. We additionally assessed the 
methodology of each trial and used data in this study that 
related to the outcome measures: glucose concentration, 
HbA1C, Zn, TG, LDL-c, HDL-c, and TC, at both baseline 
and post intervention.
Exclusion criteria
Exclusion criteria were as follows: 1) papers that were 
not available in English; (2) papers containing insuffi-
cient data required for meta-analysis; (3) papers that did 
not allow access to full texts or relevant data; (4) papers 
which were not original publications (including reviews, 
mini-reviews, letters, and comments); and (5) duplica-
tions.
Data extraction and quality assessment
The key data we collected from each of the studies were 
as follows: year of publication, country where the study 
was conducted, mean/range subject age, sample size of 
intervention and control groups, clinical condition of 
subjects, details of intervention (including the dosage of 
zinc supplementation in gram per day), type of the diet 
or intervention in the control group, intervention period, 
and significant outcomes. In addition, serum levels of 
FBG, TC, LDL-c, HDL-c, and TG were reported in mg/dL 
and HbA1c was reported as the percentage of total hae-
moglobin. For papers containing data in mmol/L, a nu-
merical conversion to mg/dL was calculated based on 
molecular weight. Serum HbA1c was represented as a 
percentage.
The Jadad scale was used as a scale to independently 
assess the methodological quality of the clinical trials. 
Jadad scoring were applied to each study, which assigns 
values ranging from 0 to 5 based on three parameters 
(randomization, blinding, and follow-up) (11). For ran-
domization, each study gets one point if randomization 
was mentioned, and one additional point if the method 
of randomization was appropriate. Moreover, one point 
is subtracted if the method of randomization was inap-
propriate. With regards to blinding, the study is assigned 
one point if blinding was mentioned, one additional point 
if the method of blinding was appropriate and one point 
for follow-up. One point is subtracted if the method of 
blinding was described inappropriately (the fate of all the 
subjects including the number and the cause of the sub-
ject’s attrition).
Statistical analysis
The meta-analysis was performed using Review Manager 
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Fig. 1. Flow diagram of included and excluded studies.
Software (RevMan 5.3; Cochrane Collaboration, Oxford, 
England). Changes is metabolic factor from baseline to 
the final measurement were calculated as mean differ-
ences (MD) with the 95% confidence interval (CIs) (12). 
Cohen’s d was used to calculate the effect size compari-
son using comprehensive meta-analysis software program 
version 2. According to Cohen’s suggestion (13), effect 
sizes of 0.2 are small, 0.5 are medium, and 0.8 or more 
are large.
A threshold of P<0.1 was set to identify the presence 
of heterogeneity. Inconsistency between the studies was 
additionally considered significant when I2>50%. A fixed 
effects model was used if I2<50% and P>0.1. A random 
effects model was used if I2>50% and P<0.1.
To identify the influence of confounding factors, sub-
group analysis were conducted according to the Cochrane 
guidelines (14). To determine the source of heterogene-
ity, we divided two subgroup analyses according to their 
design: 1) Based on the quality of the articles (those with 
three points or higher were placed in a low risk group of 
bias and those with lower than three points were placed 
in a high risk group); 2) Based on the intervention of 
zinc supplementation either alone or in combination 
with other co-supplements.
The potential for publication bias was investigated by 
visual inspection of a funnel plot. In the test, standard 
errors were plotted against the effect size for each study. 
If publication bias exists, the funnel plot demonstrates 
an asymmetric shape. The Egger regression asymmetry 
test was used to test the asymmetry of the funnel plot 
and Egger’s weighted regression test was used to statis-
tically examine and verify any potential publication bias.
RESULTS
Search results and study selection
A flow chart showing the process of literature search and 
selection is presented in Fig. 1. During the literature 
search, we identified 256 relevant articles, of which 155 
total abstracts were excluded due to duplications (n=21), 
non-English studies (n=14), reviews (n=11), and 109 
irrelevant articles such as case reports, editorials, and let-
ters. The remaining articles were considered for full-text 
review. An additional 81 articles were excluded, which 
included preclinical studies or those containing inade-
quate characterization of patients, insufficient reporting 
of data or irrelevant outcomes. Finally, based on our de-
fined inclusion and exclusion criteria, 20 papers were in-
cluded in the meta-analysis (Fig. 1). 
Study characteristics and quality assessment
Characteristics of the included studies are shown in Ta-
ble 1. The dates of publication ranged from 1992 to 2016 
(15-36). The number of participants per study ranged 
from 13 to 60, and subject ages ranged from 18 to 73 
years old. The studies investigated either the effects of 
zinc supplementation alone (15,17-19,26-28,31-34,36) 
or in combination with the other minerals and/or vita-
mins (16,20-25,29,30,35).
The dosage of zinc used in these trials ranged from 7.5 
to 660 mg/d. The zinc compounds used in the trials in-
cluded zinc sulfate (15,17,19-28,32,33,36,37), zinc chlo-
ride (16), zinc glucoronate (31,34), zinc phosphate (28), 
and zinc acetate (29,30). The length of follow up varied 
from 3 weeks to 6 months. Based on previous meta-anal-
ysis studies, which suggested studies with Jadad scores 
≥3 are high quality studies (38-40), and according to the 
quality checklist, six studies (16,19,23,29,32,33) were 
considered to be of high-quality, while the other four-
teen studies (15,17,20-22,24-28,30,31,34,36) were con-
sidered to be low-quality (Table 1).
The effects of zinc on blood glucose and lipid concentra-
tion
Since varying units for applied indices (including TG, TC, 
LDL-c, HDL-c, and FBG) were used in the included 
studies, all were converted to the same unit (mg/dL) for 
comparison. The test for overall heterogeneity indicated 
that zinc significantly effects all the investigated glycemic 
indices (Fig. 2). Subgroup analyses was therefore per-
formed to identify potential factors that could contribute 
to the heterogeneity; however, heterogeneity remained. 
Due to the observed heterogeneity between trials (mean 
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Fig. 2. Forest plots showing the association between zinc supplementation and the glycemic indices; (A) fasting blood glucose 
(FBG) and (B) hemoglobin A1c (HbA1c).
change of almost all the indicators) the random effect 
model was used to pooling data.
The serum level of FBG was analyzed in sixteen trials 
of the included studies (15,17,19,21-23,25-29,31-34,36). 
The pooled estimate showed significant differences be-
tween the mean changes of FBG and HbA1c in the treat-
ment group compared with the control group (FBG 
WMD: −19.66 mg/dL, 95% CI: −33.71, −5.62; P for 
heterogeneity <0.00001, I2=99%) (Fig. 2A). The mean 
change for HbA1c was calculated in thirteen of the in-
cluded studies (15,17,19,21-23,25,29,31-34,36). The to-
tal mean difference for HbA1c was −0.43 (95% CI: 
−0.80, −0.07; P for heterogeneity <0.00001, I2=99%) 
(Fig. 2B). The average percent change from baseline for 
FBG and HbA1c in the treated group were 9.7% and 
6.3%, respectively.
The serum level of TG was analyzed in thirteen of the 
included trials (15,16,19-21,23-25,30,32-34,36). The 
pooled mean net change of TG in the treatment group 
was −0.32 compared with the control group and was not 
statistically significant (95% CI: −1.30, 0.66; P for het-
erogeneity <0.00001, I2=96%) (Fig. 3A). The total se-
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Fig. 3. Forest plots showing the association between zinc supplementation and serum lipid indices; (A) triglyceride (TG), (B) total 
cholesterol (TC), (C) low-density lipoprotein cholesterol (LDL-c), and (D) high-density lipoprotein cholesterol (HDL-c).
rum cholesterol level was measured in thirteen of the in-
cluded trials (15,16,19-21,23-25,30,32-34,36). The pooled 
estimate showed a significant decrease in the amount of 
serum TC in the treatment group compared with the 
control group (WMD: −18.51 mg/dL; 95% CI: −21.36, 
−15.66; P for heterogeneity <0.00001, I²=99%) (Fig. 
3B). In addition, thirteen of the included trials inves-
tigated the effects of zinc supplements on the levels of 
LDL-c and HDL-c (15,16,19-21,23-25,30,32-34,36). The 
pooled mean net change in serum LDL-c was −4.80 in 
the treatment group (95% CI: −6.07, −3.53; P for het-
erogeneity <0.00001, I2=97%), which was significantly 
different from controls (Fig. 3C). The pooled WMD for 
HDL-c was 1.45 mg/dL (95% CI: 1.40, 1.51; P for heter-
ogeneity <0.00001, I²=100%), suggestive of a significant 
difference in the mean change of HDL-c between the 
two groups (Fig. 3D). The average percent change from 
baseline for LDL-c and HDL-c in the treated group were 
5.1% and 7.7%, respectively.
Effect of additional supplements
In addition, we performed a subgroup analysis based on 
the intervention (with co-supplement vs. no co-supple-
ment), shown in Table 2. Significant differences in the 
mean change of TC, LDL-c, HDL-c, and FBG levels were 
observed during subgroup analysis by “with co-supple-
ment” intervention (TC WMD: −2.31 mg/dL, 95% CI: 
−3.35 to −1.27; LDL-c WMD: −0.53 mg/dL, 95% CI: 
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Fig. 3. Continued.
−0.96 to −0.10 mg/dL; HDL-c WMD: 1.77 mg/dL, 95% 
CI: 1.72 to 1.81; FBG WMD: −2.10 mg/dL, 95% CI: 
−3.57, −0.63), consistent with the overall analysis (Ta-
ble 2). The “no co-supplement” subgroup analysis dem-
onstrated a significant difference in the mean changes in 
levels of HDL-c and FBG (HDL-c WMD: 5.38 mg/dL, 
95% CI: 4.56 to 6.19; FBG WMD: −28.20 mg/dL, 95% 
CI: −44.32, −12.08) (Table 2).
Effect of study quality
The subgroup analysis for high-quality studies confirmed 
a significant difference in the mean change of LDL-c, 
HDL-c, and FBG (LDL-c WMD: −2.22, 95% CI: −4.16, 
−0.27; HDL-c WMD: 0.09, 95% CI: 0.02, 0.16; FBG 
WMD: 0.52, 95% CI: 0.11, 0.93). The low-quality stud-
ies showed a significant increase in all indices except for 
TG, which was consistent with the overall results (TC 
WMD: −17.66 mg/dL, 95% CI: −20.17, −15.15; LDL-c 
WMD: −20.37 mg/dL, 95% CI: −22.32, −18.43; HDL-c 
WMD: 2.60 mg/dL, 95% CI: 2.55, 2.65; FBG WMD: 
−27.35 mg/dL, 95% CI: −41.38, −13.32; HbA1c WMD: 
−0.54%, 95% CI: −0.92, −0.15). However, compared 
with the overall results, heterogeneity was not related to 
decreases in the subgroup analysis of interventions and 
quality assessment of trials (Table 2).
Effect size
To explore the effectiveness of zinc supplementation, the 
size of the effect within the 20 studies included in this 
meta-analysis was explored. Zinc supplementation great-
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Table 2. Subgroup analysis
Subgroup Intervention Quality of studyCo-supplement No co-supplement Low quality High quality
TG
WMD (95% CI) −0.24 (−0.63, 0.15) −4.21 (−40.59, 32.18) −0.43 (−1.03, 0.17) −0.01 (−0.63, 0.61)
Test for heterogeneity (I2, P) 96%, P<0.00001 97%, P<0.00001 94%, P<0.00001 92%, P<0.00001
Test for overall effect P=0.23 P=0.82 P=0.04 P=0.97
Cohen’s d (95% CI) −0.14 (−1.31, 0.32) −0.18 (−1.24, 0.87) −0.49 (−1.30, 0.31) −0.19 (−1.23, 0.86)
TC
WMD (95% CI) −2.31 (−3.35, −1.27) −37.79 (−79.91, 4.34) −17.66 (−20.17, −15.15) −0.66 (−2.07, 0.75)
Test for heterogeneity (I2, P) 98%, P<0.00001 97%, P<0.00001 99%, P<0.00001 94%, P<0.00001
Test for overall effect P<0.0001 P=0.08 P<0.0001 P=0.36
Cohen’s d (95% CI) −1.68 (−2.81, −0.54) −0.73 (−1.17, −0.63) −2.35 (−3.35, −1.35) −0.24 (−1.44, 0.95)
LDL-c
WMD (95% CI) −0.53 (−0.96, −0.10) −13.89 (−28.97, 1.19) −20.37 (−22.32, −18.43) −2.22 (−4.16, −0.27)
Test for heterogeneity (I2, P) 90%, P<0.00001 97%, P<0.00001 99%, P<0.00001 97%, P<0.00001
Test for overall effect P<0.02 P=0.07 P<0.0001 P=0.03
Cohen’s d (95% CI) −1.31 (−2.04, −0.59) −0.39 (−2.20, −0.13) −2.03 (−2.58, −1.47) 0.81 (0.33, 0.98)
HDL-c
WMD (95% CI) 1.77 (1.72, 1.81) 5.38 (4.56, 6.19) 2.60 (2.55, 2.65) 0.09 (0.02, 0.16)
Test for heterogeneity (I2, P) 100%, P<0.00001 99%, P<0.00001 100%, P<0.00001 100%, P<0.00001
Test for overall effect P<0.00001 P<0.00001 P<0.0001 P=0.02
Cohen’s d (95% CI) 1.11 (0.83, 1.40) 0.90 (0.64, 1.16) 1.12 (0.89, 1.35) 0.81 (0.33, 0.98)
FBG
WMD (95% CI) −2.10 (−3.57, −0.63) −28.20 (−44.32, −12.08) −27.35 (−41.38, −13.32) 0.52 (0.11, 0.93)
Test for heterogeneity (I2, P) 95%, P<0.00001 99%, P<0.00001 99%, P<0.00001 57%, P=0.05
Test for overall effect P=0.005 P=0.0006 P=0.0001 P=0.01
Cohen’s d (95% CI) −0.90 (−1.89, 0.10) −2.54 (−3.61, −1.48) −2.48 (−3.40, −1.56) 0.82 (0.27, 1.26)
HbA1c
WMD (95% CI) −0.35 (−0.84, 0.14) −0.44 (−0.86, −0.01) −0.54 (−0.92, −0.15) 0.05 (−0.12, 0.21)
Test for heterogeneity (I2, P) 98%, P<0.00001 99%, P<0.00001 99%, P<0.00001 71%, P=0.02
Test for overall effect P=0.16 P=0.07 P=0.007 P=0.59
Cohen’s d (95% CI) −0.34 (−1.72, 0.84) −0.22 (−1.17, 0.47) −2.12 (−3.26, −0.98) 0.35 (−0.45, 1.14)
WMD, weighted mean difference; CI, confidence interval; TG, triglycerides; TC, total cholesterol; LDL-c, low-density lipoprotein 
cholesterol; HDL-c, high-density lipoprotein cholesterol; FBG, fasting blood glucose; HbA1c, hemoglobin A1c.
ly impacted on levels of FBG (d=−1.73, 95% CI: −2.53, 
−0.94), HbA1c (d=−1.63, 95% CI: −2.55, −0.71), 
HDL-c (d=1.44, 95% CI: 0.56, 2.33), LDL-c (d=−1.28, 
95% CI: −1.95, −0.61), and TC (d=−1.99, 95% CI: 
−2.87, −1.11) but only had a small, non-significant ef-
fect on levels of TG (d=−0.15, 95% CI: −0.79, 0.49) 
(Fig. 4).
We conducted further subgroup analysis based on in-
tervention and study quality. In studies analyzing the ef-
fects of zinc with co-supplements, a large effect size was 
found for TC (d=−1.68, 95% CI: −2.81, −0.54), LDL-c 
(d=−1.31, 95% CI: −2.04, −0.59), and HDL-c (d= 
1.11, 95% CI: 0.83, 1.40). Only FBG had a large and sig-
nificant effect size in the no co-supplement group (d= 
−2.54, 95% CI: −3.61, −1.48) (Table 2).
In high quality studies, all outcomes showed small 
non-significant effect sizes in the intervention group 
compared with the control group. However, low quality 
studies showed large effect sizes for HDL-c (d=1.12,       
                                                                                     
95% CI: 0.89, 1.35), LDL-c (d=−2.03, 95% CI: −2.58, 
−1.47), TC (d=−2.35, 95% CI: −3.35, −1.35), FBG 
(d=−2.48, 95% CI: −3.40, −1.56), and HbA1c (d= 
−2.12, 95% CI: −3.26, −0.98), but small effect sizes 
for the remaining parameters (Table 2).
Publication bias
In this meta-analysis, publication bias was assessed by 
examining funnel plot of the effects on LDL-c as a repre-
sentative index for the lipid profile, and FBG as a repre-
sentative index for glycemic status. Based on visual in-
spection of the plots, there was some evidence of pub-
lishing bias regarding studies of zinc supplementation 
on both LDL-c and FBG. This was confirmed by Egger’s 
linear regression (LDL-c: intercept: −3.9; standard error: 
1.41; 95% CI: −7.03, −0.79; t=2.75, df=11; two-tailed 
P=0.01; FBG: intercept: −8.2; standard error: 3.11; 95% 
CI: −14.90, −1.53; t=2.63, df=14; two-tailed P=0.01) 
(Fig. 5).
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Fig. 4. Results of meta-analysis, Forest plot of point estimate effect sizes reported as Cohen’s d (X-axis) evaluating zinc supple-
mentation on (A) fasting blood glucose (FBG), (B) hemoglobin A1c (HbA1c), (C) triglyceride (TG), (D) total cholesterol (TC), (E) low-den-
sity lipoprotein cholesterol (LDL-c), and (F) high-density lipoprotein cholesterol (HDL-c) using the random effects model. Points 
represent weighted effect size, lines represent 95% confidence intervals (CIs). Triangle indicates overall effect size and 95% CI.
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Fig. 5. Funnel plot of studies included in the meta-analysis for the outcome of (A) low-density lipoprotein cholesterol (LDL-c) 
and (B) fasting blood glucose (FBG). MD, mean difference; SE, standard error.
DISCUSSION 
Our meta-analysis of 20 clinical trials demonstrated that 
zinc supplementation leads to a significant reduction in 
the concentration of all diabetic markers measured ex-
cept TG. Using Cohen’s criteria for effect size categoriza-
tion (13), we showed that the effect of zinc supplemen-
tation was large for FBG, HbA1c, HDL-c, LDL-c, and TC 
and small for TG. The effects of zinc supplementation 
were investigated in trials that supplemented zinc as an 
investigated intervention alone or in combination with 
the other micronutrients. This meta-analysis showed zinc 
supplementation significantly reduces overall serum glu-
cose concentrations. Moreover, the analyzed studies in-
dicated that zinc supplementation significantly decreases 
serum glucose concentration, levels of HbA1c, LDL-c, and 
TC, and increases concentrations of HDL-c, while it did 
not significantly effect TG.
Our data demonstrates positive clinical and therapeu-
tical effects of zinc supplements for patients with DM. It 
suggests that zinc is responsible for improving glycemic 
and lipid profile controls. In general, these findings are 
consistent with results of most of the individual studies; 
of the 20 included studies, only four trials reported no 
beneficial effects of zinc supplementation on glycemic 
and lipidemic statuses. The reasons provided are: small 
sample sizes and low dosages of zinc supplements used 
(16,23,31,34). Moreover, the diversity of zinc compounds 
may have affected the results.
The data showed that heterogeneity among studies was 
significant. Subgroup analysis revealed that the effects of 
zinc supplement may differ by factors such as interven-
tion regimens (zinc supplements alone or in combination 
with the other co-supplements) and quality assessment. 
Subgroup analysis based on quality assessment reduced 
the high heterogeneity of mean changes of FBG in sub-
groups of high quality studies.
Subgroup analysis by intervention regimens
Subgroup analysis of intervention regimens (zinc sup-
plements in combination with the co-supplements) in-
dicated that the result of zinc supplementation on meta-
bolic indicators is consistent with the overall analysis, 
with the exception of for serum HbA1c. There is there-
fore a discrepancy between the overall results and the 
subgroup analysis of “co-supplements” and “no co-sup-
plements”. Magnesium, vitamin C, and vitamin E were 
the co-supplements used in most of the included trials 
and their co-ingestion with zinc could promote further 
effects on markers of interest. A meta-analysis of 9 ran-
domized controlled trials reported that oral magnesium 
supplementation was effective in reducing fasting plas-
ma glucose and rising HDL-c in type 2 diabetic subjects, 
but without inducing significant effects on TC, TG, and 
LDL-c (41). Paolisso et al. (42) suggested that chronic 
administration of vitamin C exerts beneficial effects upon 
glucose and lipid metabolism in elderly type 2 diabetic 
subjects, however the supporting trials are limited in 
number. The other most frequently administrated co- 
supplement was vitamin E; a systematic review and met-
a-analysis in 2011 suggested no beneficial effects of vita-
min E supplementation on glycemic control. However, 
authors of this study suggested that HbA1c could de-
crease with vitamin E supplementation in subjects with 
poor glycemic control or low vitamin E levels (43). Oth-
er components analyzed were used sporadically in the 
trials and were therefore found to have the least effect. 
However, the roles of these compounds cannot be ignor-
ed, especially for vitamin D and chromium.
A previous study has demonstrated a positive relation-
ship between FBS and HbA1c (44), however this associ-
ation was not supported in others studies, possibly due 
to individual study designs. Derakhshan et al. (45) did 
not observe any association between HbA1c and blood 
glucose in type 1 diabetic patients; this may be explained 
by the younger ages of subjects in the study and its low 
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power. Another study investigating subjects with diabet-
ics and impaired blood glucose levels showed that the 
sensitivity and the specificity of HbA1c were 88% and 
93.75%, respectively (46). This was similar to the find-
ings by Ghazanfari et al. (47), which concluded that FBS 
is more reliable than HbA1c for separating diabetic from 
non-diabetic subjects.
Subgroup analysis based on zinc supplements alone 
showed significant improvements in HDL-c and FBG lev-
els. Combination of zinc supplemention with other vita-
min/mineral supplements exhibited favorable effects on 
nearly all metabolic indicators. Zinc supplementation 
alone may therefore affect FBG and HDL-c, but changes 
to the other investigated metabolic markers may depend 
on the addition of other co-supplements.
Results from the effect size analysis showed that zinc 
supplementation in combination with other supplements 
can induce large changes to levels of TC, HDL-c, and 
LDL-c, however zinc supplementation alone is likely to 
only induce a large effect on FBG. In clinical practice, 
zinc supplements should be combined with other sup-
plements to improve lipid markers in addition to serum 
FBG.
Subgroup analysis by quality assessment
Another analysis was conducted based on quality assess-
ment. Low quality studies showed significant differences 
in the mean changes of all investigated indicators. How-
ever, in high quality studies, significant differences were 
found in the mean changes of levels of LDL-c, HDL-c, and 
FBG. After carrying out analysis of effect size, low qual-
ity studies showed large effects for zinc supplementation 
on glycemic markers and levels of serum LDL-c, HDL-c, 
and TC; however, high quality studies did not show any 
significant effects on the outcomes of interest. These re-
sults indicate that high quality studies did not show large 
effects of zinc supplementation on lipid or glycemic mar-
kers, however low quality studies were able to confirm 
some clinical benefits.
Overall, the analysis carried out in this study showed 
that FBG and HDL-c are the most significantly affected 
markers by zinc supplementation. Diabetic subjects sup-
plemented with zinc (with or without other co-supple-
ments), should expect a significant reduction in serum 
FBG, and elevation in HDL-c. This result is consistent 
with our subgroup analysis of high quality studies, with 
the exception of LDL-c.
However, subgroup analysis did not reduce high heter-
ogeneity for mean changes of all markers (except for 
FBG) in the high quality studies. The source of hetero-
geneity therefore remains unknown.
Several meta-analyses studies have investigated the ef-
fects of zinc supplementation on diabetic or healthy sub-
jects. Jayawardena et al. showed a significant reduction 
in systolic and diastolic blood pressures following zinc 
supplementation. The study demonstrated the beneficial 
effects of zinc supplementation on glycemic control and 
healthy lipid parameters in patients with diabetes (8). 
The review consisted of 12 studies which compared the 
effects of zinc supplementation on FBG in patients with 
type 2 diabetes, and 8 studies comparing the effects of 
zinc supplementation on serum lipid profiles. In the cur-
rent review, we included 4 additional studies investigat-
ing the effects of zinc supplementation on glycemic sta-
tus (19,23,31,36) and 5 additional studies on the effects 
of serum lipid profiles (16,19,23,25,36).
A further review showed a significant, albeit modest, 
reduction in glucose concentrations following zinc sup-
plementation, and a tendency for reductions in mean lev-
els of HbA1c. The authors suggested that zinc may con-
tribute to the management of hyperglycemia in individu-
als with chronic metabolic disease (48).
In the recent meta-analysis, Ranasinghe et al. showed 
that zinc supplementation had significantly reduces total 
serum cholesterol, LDL-c, and TG on plasma lipid param-
eters in patients with different health statuses (49). The 
authors analyzed 14 trials which included healthy pa-
tients and patients with various health conditions such 
as chronic metabolic diseases (types 1 and 2 DM, meta-
bolic syndrome, and obesity). A total of 8 studies, which 
included subjects with type 2 diabetes, were also in-
cluded in the current meta-analysis (17,20,21,24,26,31, 
33,34); an additional 8 studies were added in this up-
dated study (15,19,23,27-29,32,36). This study is there-
fore the most comprehensive meta-analysis to date, eval-
uating whether zinc supplementation impacts serum lip-
id profiles and glycaemic status in diabetic patients. Fur-
thermore, this is the first meta-analysis to investigate the 
effects of zinc supplementation based on distinct sub-
groups, intervention and quality assessment.
Several studies have suggested that supplementation 
with vitamins and minerals such as vitamins C and E, 
and magnesium may ameliorate the severity of many di-
abetic symptoms in patients (24,35,50). Moreover, that 
zinc supplementation improves the symptoms of T2DM 
and may lead to improvement of factors such as microal-
buminuria, insulin secretion, homocsteine concentration, 
glucagon, glucose-6-phosphate, vitamin B12, and folate 
(BH5) (22,24). However, cohort studies have revealed 
different outcomes for the association between zinc in-
take and serum glucose concentrations (51) and the risk 
of T2DM (52); multiple studies have demonstrated that 
zinc is inversely associated with cardiovascular disease 
(CVD) risk factors in diabetic subjects (50,53). These 
findings are consistent with the conclusions presented 
in the present meta-analysis. 
Multiple molecular mechanisms are known to affect 
glycaemic status after zinc supplementation of patients 
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with T2DM, including interactions between zinc and the 
insulin receptors, the structural integrity of insulin, and 
insulin signaling pathways (1,37,54). Zinc exerts insulin- 
like effects by stimulating phosphorylation of the insulin 
receptor β-subunit. Zinc can therefore influence phos-
phorylation of glucose receptors. Zinc can additionally 
mediate PI3K/Akt insulin-signaling pathway (1,37,54). 
Two families of zinc transporters are involved in main-
taining intracellular zinc homoeostasis. These transport-
ers onsist of the ZnT (SLC30) and ZiP (SLC390) trans-
porter families (55). ZnT transporters act to elevate cel-
lular zinc efflux and sequestration of zinc into intra-cel-
lular organelles, and ZiP transporters transport zinc 
from outside the cells and from in intracellular compart-
ments into the cytoplasm (55). ZnT8 co-localizes with 
insulin in human pancreatic islets is thought to be in-
volved in both insulin granule zinc accumulation and 
regulation of insulin secretion in β-cells (56). Studies 
suggest that zinc transporters can affect both α- and 
β-cell function (56,57). Reducing insulin resistance and 
improving insulin secretion inhibits lipolysis in adipose 
tissues, reducing free fatty acid release and its availabili-
ty to the liver, which prevents excessive lipoprotein syn-
thesis. Moreover, Ginsberg et al. demonstrated that zinc 
deficiency downregulates fatty acid utilization in mito-
chondria and peroxisomes, and upregulates lipid synthe-
sis in the liver of rat (58). Zinc can further regulate the 
activity of inducible nitric oxide syntnase, reversing the 
adverse effects of inflammation on the endothelium (59), 
and may reduce atheroma formation and plasma and ar-
terial wall lipid peroxidation in rabbits fed on a high lip-
id and cholesterol diet (5). These animal models provide 
biological plausibility for a beneficial role of zinc in CVD 
prevention. Rodent models have further demonstrated 
that zinc may play important roles in the synthesis, se-
cretion and function of insulin under normal physiologi-
cal conditions, and that zinc supplementation may be 
protective in animal models of type 2 diabetes (60). In 
human, low serum zinc has been associated with diabe-
tes, but this is thought likely due to hyperzincuria and 
impaired zinc absorption (61). One study reported a 
lower incidence of type 2 diabetes in patients with higher 
intakes of dietary zinc (62). However, oxidative stress, 
which is common in diabetic patients, may be reduced 
by zinc supplementation (52). Other supplements, such 
as selenium and magnesium, are indicated for relieving 
diabetes complications, similar to zinc supplements. 
However, the association between selenium and glucose 
metabolism has yielded inconsistent results within sev-
eral studies: a prospective epidemiology study has linked 
high selenium status with a reduced risk of diabetes pro-
gression (63), while a study by the US National Health 
and Nutrition Examination associated high serum sele-
nium with increased incidence of type 2 diabetes (64). A 
further study by Gao et al. did not find an association 
between selenium status with insulin secretion, insulin 
sensitivity, or risk of type 2 diabetes (65). Therefore, the 
exact role of selenium in progression of diabetes re-
mains uncertain.
A further study by Guerrero et al. showed an associa-
tion between hypomagnesaemia, impaired glucose toler-
ance and type 2 diabetes, but not with impaired fasting 
glucose (66). However, several reports have shown that 
patients with pre-diabetic and type 2 diabetic may have 
significant magnesium deficiencies (67). A study by 
Hruby et al. concluded that participants with higher 
magnesium intakes are about 32 to 47 percent less likely 
to develop incident diabetes, therefore supporting a role 
of magnesium intake for protection against development 
of overt diabetes (6). However, the mechanism of action 
remains inconclusive. Our studies suggest that zinc sup-
plementation may be one of the most important factors 
for alleviating complications in diabetes, next to other 
trace elements such as selenium and magnesium. 
In some trials, the dosage of zinc was greater than the 
recommended upper limit of 40 mg/d (15,26,27,29-31, 
33,34,36); high dosages of zinc may cause copper defi-
ciencies and adversely affect antioxidant enzymes such 
as superoxide dismutase (68). It has been suggested that 
zinc supplementation may lead to iron deficiency in fe-
males, especially those with low levels of iron storage 
(69). In another study, zinc supplementation was linked 
to abdominal pain (15), however the cause and effect re-
lationship was not proved (8). In addition, a meta-analy-
sis revealed that zinc supplementation may lead to atten-
uation of plasma HDL-c levels (9) after administration 
of zinc dosages higher than 50 mg/d for longer than 3 
months (68). Doses of zinc ≥150 mg/d may further re-
sult in immune dysfunction (70). In this study, we no-
ticed that the observed metabolic results of the 20 mg/d 
zinc dose are closest to the overall findings. Therefore, 
we can assume 20 mg/d is the optimal zinc dosage for 
improvement of metabolic indices. Despite the noted 
benefits of zinc supplementation on metabolic indices of 
diabetic patients, further research may be required be-
fore the benefits of zinc supplementation are concluded. 
Limitations in the present meta-analysis include ex-
clusion of papers not written in English and those only 
found on other electronic databases. As the authors of 
this paper only spoke English, we were unable to include 
papers that published in other languages; future meta- 
analyses should include these papers to increase con-
fidence in the conclusions. A further limitation of the 
study was that we had insufficient data from some of pa-
pers for the meta-analysis, despite attempts to obtain 
the data from the authors. 
Residual confounders are considered a further limita-
tion. We were unable to rule out potential confounding 
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due to unmeasured variables in the included studies, such 
as patient selection, family history, type of test used, pa-
tient selection, clinical setting, and formulation of sup-
plements. Moreover, dietary factors (such as restricted 
access to data of dietary intake of zinc, energy, vegeta-
bles, fat) differed between studies, which may increase 
confounding bias. Furthermore, there may be potential 
publication bias since there was remarkable heteroge-
neity among the included studies. The observed funnel 
plot asymmetry could be partly defined by the heteroge-
neity in the measurements. This variation may be caused 
by chance alone (small sample sizes) or errors in calcu-
lating measures of accuracy statistics, but could also re-
flect true heterogeneity.
Contrary to these limitations, the current meta-analy-
sis has considerable strengths including the quantity of 
subjects included, lack of publication bias, and the use of 
a random effects model of meta-analysis for assessing 
study heterogeneity. In addition, studies were assessed 
using subgroup analysis based on intervention and qual-
ity assessment.
In conclusion, this meta-analysis found that adminis-
tration of zinc supplements may improve lipid metabo-
lism and glucose homeostasis in patients with type 2 di-
abetes. Since the calculated effect sizes were categorized 
as large effects for most of the parameters studies, the 
significant effects should be considered clinically. Al-
though the overall analysis showed significant changes 
in nearly all indicators, subgroup analyses found that 
changes that are more noticeable for FBG, LDL-c, and 
HDL-c. Further research is warranted on larger sample 
sizes to determine the effectiveness, optimal dosage, and 
duration of zinc supplementation to induce maximal pos-
itive effects.
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